Financing

Innocrin raises $28 million in series D financing

Posted on 15 April 2015

Tags:

Innocrin Pharmaceuticals announced the completion of a $28 million Series D financing round.

The financing was led by Eshelman Ventures and Fred Eshelman, PharmD., Founder of Eshelman Ventures, has joined Innocrin’s board of directors.

The company’s current investors: Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, and A&B Equity Holdings all participated in the fully subscribed round.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Innocrin plans to use the proceeds to accelerate parallel Phase 2 CRPC program studies that are being led by the Memorial Sloan Kettering Cancer Center (MSK) and the NCI.

The company will also initiate an MSK-led Phase 1 / 2 study in women who have resistant breast cancer that either expresses the estrogen receptor (ER+ subtype) or does not express any of the accepted treatment biomarkers (triple-negative breast cancer or TNBC).

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply